Active Watch List : Johnson & Johnson (NYSE:JNJ), Applied Materials, Inc. (NASDAQ:AMAT), PTC Therapeutics, Inc. (NASDAQ:PTCT), DIRECTV (NASDAQ:DTV), Phillips 66 Partners (NYSE:PSXP)

Johnson & Johnson (NYSE:JNJ) announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. The acquisition will include Alios BioPharma’s portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with … Continue reading Active Watch List : Johnson & Johnson (NYSE:JNJ), Applied Materials, Inc. (NASDAQ:AMAT), PTC Therapeutics, Inc. (NASDAQ:PTCT), DIRECTV (NASDAQ:DTV), Phillips 66 Partners (NYSE:PSXP)

Chris Lewis10/0210/02

Healthcare Active Movers: Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), PTC Therapeutics, Inc. (NASDAQ:PTCT), Inovio Pharmaceuticals Inc (NYSEMKT:INO)

US drugmaker Pfizer Inc (NYSE:PFE) on Monday abandoned its pursuit to buy AstraZeneca PLC, saying it does not plan to make an offer for the British drugmaker following the rejection of its final proposal last week. Pfizer Inc. (NYSE:PFE) stock performance was -0.57% in last session and finished the day at $29.49. Traded volume was 18.93million shares in the last session and the average volume … Continue reading Healthcare Active Movers: Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), PTC Therapeutics, Inc. (NASDAQ:PTCT), Inovio Pharmaceuticals Inc (NYSEMKT:INO)

Jayne Crisman05/2705/27

Notable Movers: ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), PTC Therapeutics, Inc. (NASDAQ:PTCT), Orexigen Therapeutics, Inc. (NASDAQ:OREX), CytRx Corporation (NASDAQ:CYTR), ZIOPHARM Oncology (NASDAQ:ZIOP)

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) presented results from a global, multi-center, open-label, comparator-controlled phase II study in patients undergoing total knee replacement surgery or total knee arthroplasty (TKA). Two doses of ISIS-FXIRx (200mg, 300mg) were compared to Sanofi’s Lovenox (enoxaparin). ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stock performance was 11.26% in last session and finished the day at $27.81. Traded volume was 4,554,523 shares in the last session … Continue reading Notable Movers: ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), PTC Therapeutics, Inc. (NASDAQ:PTCT), Orexigen Therapeutics, Inc. (NASDAQ:OREX), CytRx Corporation (NASDAQ:CYTR), ZIOPHARM Oncology (NASDAQ:ZIOP)

Kristen Barton05/2705/27

Biotech Losers: PTC Therapeutics (NASDAQ:PTCT), Prosensa Holding (NASDAQ:RNA), Concert Pharmaceuticals Inc (NASDAQ:CNCE), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), Agios Pharmaceuticals Inc (NASDAQ:AGIO)

One solution, developed by PTC Therapeutics Inc. (NASDAQ:PTCT), a US biotechnology company, is to intervene in the transcription process in which the DNA is converted first to messenger RNA and then into protein. PTC Therapeutics Inc. (NASDAQ:PTCT)’s experimental drug ataluren is designed to override the false stop signal by interacting with the ribosome – the tiny biological machine inside every cell that runs along messenger … Continue reading Biotech Losers: PTC Therapeutics (NASDAQ:PTCT), Prosensa Holding (NASDAQ:RNA), Concert Pharmaceuticals Inc (NASDAQ:CNCE), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Richard Atkins05/1605/16

FB Nasdaq FB Facebook

Biotech Volatile Stocks: PTC Therapeutics (NASDAQ:PTCT), Agios Pharmaceuticals Inc (NASDAQ:AGIO), BioCryst Pharmaceuticals (NASDAQ:BCRX), TG Therapeutics (NASDAQ:TGTX)

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. In April 2013, PTC Therapeutics, Inc. (NASDAQ:PTCT) initiated the confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) clinical trial evaluating ataluren as a potential treatment for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC Therapeutics, Inc. (NASDAQ:PTCT) stock performance … Continue reading Biotech Volatile Stocks: PTC Therapeutics (NASDAQ:PTCT), Agios Pharmaceuticals Inc (NASDAQ:AGIO), BioCryst Pharmaceuticals (NASDAQ:BCRX), TG Therapeutics (NASDAQ:TGTX)

Colin Pettis04/0704/07

Biotech Bearish Stocks: Reliv International (NASDAQ:RELV), Ocera Therapeutics (NASDAQ:OCRX), MediciNova (NASDAQ:MNOV), PTC Therapeutics (NASDAQ:PTCT)

Registrant and three of its wholly-owned subsidiaries, Reliv, International, Inc (NASDAQ:RELV), Reliv World Corporation and SL Technology, Inc. entered into a Credit Agreement with BMO Harris Bank N.A. (the “Bank”) pursuant to which the Bank agreed to provide certain credit facilities to Registrant, including a Term Loan in the principal amount of $3,481,961 and a revolving credit facility in the amount of $5,000,000. Reliv International, … Continue reading Biotech Bearish Stocks: Reliv International (NASDAQ:RELV), Ocera Therapeutics (NASDAQ:OCRX), MediciNova (NASDAQ:MNOV), PTC Therapeutics (NASDAQ:PTCT)

Jayne Crisman04/0304/03